Saudi Arabia Pharmaceuticals Market: By Product Type (Prescription Products and OTC Products), By Diseases Type (Diabetes, Cardiovascular Diseases, Cancer, Neurological Disorders, Obesity, Infectious Diseases, and Others), By Distribution Channel (Hospital Pharmacies and Retail Pharmacies).

Purchase Option

$ 3100
$ 4600
$ 6900

Saudi Arabia Pharmaceuticals Market size was valued at USD 7,979.17 million in 2022 and is poised to grow at a CAGR of 6.8% from 2024-2030. The desire for branded or second-generation pharmaceuticals among key stakeholders such as patients and prescribers is creating a plethora of opportunities for global companies in the country. These brands are typically distributed through partnerships with local pharmaceutical businesses, which enable new entrants into the market to access a larger number of pharmacies around the country. Furthermore, Saudi Arabia is heavily reliant on pharmaceutical imports from diverse geographies, which are mostly dominated by global pharmaceutical behemoths that supply innovative and second-tier brands through local companies. Brand loyalty for multinational firm products can be related to the medication's quality and accessibility, which helps multinational players get a bigger market share. 

Saudi Arabia Pharmaceuticals Market Dynamics

The preference for branded drugs or second brands among key stakeholders such as patients and prescribers are creating the ample opportunities for multinational players in the country. These brands generally sold through the alliance with local pharmaceutical companies which help the new players in the market to reach wider pharmacies across the country. Moreover, Saudi Arabia largely dependent upon imports for pharmaceuticals from various geographies and mainly dominated by the multinational pharmaceutical giants who offer innovative and second brands through local players. Brand loyalty for multinational company products can be attributed to the quality and accessibility of the medication which helps in garnering larger market share by multinational players. Rising prevalence of various chronic diseases such as diabetes, ischemic heart disease, stroke, obesity, hypertension, cancer among Saudi nationals is creating market demand pharmaceuticals in the country. Drug treating chronic ailments are expected to provide lucrative market opportunities for the players in the country. Moreover, these chronic diseases are a major cause of death in Saudi Arabia.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Saudi Arabia Pharmaceuticals Market Segmentation

By Product Type
  • Prescription Products
  • OTC Products
By Disease Type
  • Diabetes
  • Cardiovascular Diseases
  • Cancer
  • Neurological Disorders
  • Obesity
  • Infectious Diseases
  • Others

 

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies

Frequently Asked Questions

The Saudi Arabia pharmaceuticals market size was valued at USD 7,979.17 million in 2022

GlaxoSmithKline plc. , Riyadh Pharma , SPIMACO, Tabuk Pharmaceuticals Manufacturing Co.

The Saudi Arabia pharmaceuticals market segments are by product type, disease type and distribution channel

1. Research Methodology

      1.1. Secondary and Primary research

            1.1.1. Secondary Sources

            1.1.2. Primary Sources

      1.2. Market Revenue Estimation Methodology

      1.3. Key Assumptions

      1.4. Acronyms

2. Scope of Study

      2.1. Market Definition

      2.2. Objective of the Research

      2.3. Regions covered in the study

3. Executive summary

4. Saudi Arabia Pharmaceuticals Market Dynamics

      4.1. Drivers

            4.1.1. Economic Drivers

            4.1.2. Demand Side Drivers

            4.1.3. Supply Side Drivers

      4.2. Restraints

      4.3. Opportunities/Unmet Needs of the Market

      4.4. Trends

5. Unique Features of the Report

      5.1. Competition analysis

      5.2. Regulatory landscape

      5.3. PESTLE analysis

      5.4. Porter’s analysis

6. Saudi Arabia Pharmaceuticals Market Analysis, By Product Type, 2018 - 2022 and Forecast, 2023 - 2029

      6.1. Prescription Products

            6.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      6.2. OTC Products

            6.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. Saudi Arabia Pharmaceuticals Market Forecast, By Disease Type Analysis, 2018 - 2022 and Forecast, 2023 - 2029

      7.1. Diabetes

            7.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      7.2. Cardiovascular Diseases

            7.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      7.3. Cancer

            7.3.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      7.4. Neurological Disorders

            7.4.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      7.5. Obesity

            7.5.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      7.6. Infectious Diseases

            7.6.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            7.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      7.7. Others

            7.7.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            7.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. Saudi Arabia Pharmaceuticals Market Forecast, By Distribution Channel Analysis, 2018 - 2022 and Forecast, 2023 - 2029

      8.1. Hospital Pharmacies

            8.1.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

      8.2. Retail Pharmacies

            8.2.1. Market Analysis, 2015 – 2019 and Forecast, 2020 – 2026(Revenue, USD Mn)

            8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. Competition Landscape

      9.1. Strategic Dashboard of Top Market Players

      9.2. Company Profiles (Introduction, Financial Analysis, Component & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

            9.2.1. GlaxoSmithKline plc. (UK)

            9.2.2. Jamjoom Pharma (Saudi Arabia)

            9.2.3. Juphar (UAE)

            9.2.4. Novartis AG (Switzerland)

            9.2.5. Pfizer Inc. (US)

            9.2.6. Riyadh Pharma (Saudi Arabia)

            9.2.7. Sanofi (France)

            9.2.8. SPIMACO (Saudi Arabia)

            9.2.9. Tabuk Pharmaceuticals Manufacturing Co. (Saudi Arabia)

10. Key Assumptions and Acronyms

  • GlaxoSmithKline plc. (UK)
  • Jamjoom Pharma (Saudi Arabia)
  • Juphar (UAE)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (US)
  • Riyadh Pharma (Saudi Arabia)
  • Sanofi (France)
  • SPIMACO (Saudi Arabia)
  • Tabuk Pharmaceuticals Manufacturing Co. (Saudi Arabia)

Adjacent Markets